(PRPO) Precipio - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74019L5030
PRPO: Diagnostic Testing, Cell Culture Media, Genetic Panels, Biomarkers
Precipio, Inc. (NASDAQ:PRPO) is a healthcare solutions provider specializing in diagnostic products, reagents, and services for blood cancer testing. The company offers innovative solutions such as IV-Cell, a proprietary cell culture media designed to culture four hematopoietic cell lineages simultaneously, enhancing diagnostic accuracy and efficiency. Additionally, HemeScreen provides a comprehensive suite of genetic diagnostic panels tailored for hematological disorders. Precipio also serves bio-pharma companies with biomarker testing and clinical project services. Headquartered in New Haven, Connecticut, the company operates at the intersection of diagnostics and precision medicine.
Based on technical indicators, PRPOs short-term outlook appears bearish. The stock is trading below its 20-day SMA of 7.66, with a last price of 7.15. The 50-day SMA at 6.78 suggests downward momentum, while the 200-day SMA of 6.12 indicates longer-term weakness. Average volume of 6,156 shares over 20 days reflects limited liquidity, and an ATR of 0.54 signals moderate volatility.
Fundamentally, Precipios market cap of $8.89M reflects its micro-cap status, with a P/S ratio of 0.57 indicating modest revenue generation relative to its market value. The P/B ratio of 0.83 suggests the stock may be undervalued relative to book value. However, the negative RoE of -25.12% highlights profitability challenges. The forward P/E of 15.43 implies expectations of future earnings growth, though this remains speculative given current performance metrics.
Over the next three months, PRPO is expected to face continued pressure due to its declining SMA trends and negative profitability. However, potential catalysts such as new contracts or regulatory approvals could drive short-term volatility. Investors should monitor volume trends and any updates on the companys pipeline or partnerships.
Additional Sources for PRPO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRPO Stock Overview
Market Cap in USD | 9m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2000-07-18 |
PRPO Stock Ratings
Growth 5y | -55.1% |
Fundamental | -25.1% |
Dividend | 0.0% |
Rel. Strength Industry | 18.3 |
Analysts | 5/5 |
Fair Price Momentum | 6.40 USD |
Fair Price DCF | - |
PRPO Dividends
No Dividends PaidPRPO Growth Ratios
Growth Correlation 3m | 87% |
Growth Correlation 12m | 38% |
Growth Correlation 5y | -83.4% |
CAGR 5y | -19.33% |
CAGR/Max DD 5y | -0.20 |
Sharpe Ratio 12m | -0.06 |
Alpha | 14.29 |
Beta | 0.13 |
Volatility | 77.78% |
Current Volume | 0.7k |
Average Volume 20d | 6.5k |
As of March 15, 2025, the stock is trading at USD 7.16 with a total of 743 shares traded.
Over the past week, the price has changed by +3.39%, over one month by -0.86%, over three months by +22.05% and over the past year by +19.33%.
Probably not. Based on ValueRay Fundamental Analyses, Precipio (NASDAQ:PRPO) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.06 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRPO as of March 2025 is 6.40. This means that PRPO is currently overvalued and has a potential downside of -10.61%.
Precipio has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy PRPO.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PRPO Precipio will be worth about 6.9 in March 2026. The stock is currently trading at 7.16. This means that the stock has a potential downside of -3.49%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 19 | 165.4% |
Analysts Target Price | 40 | 458.7% |
ValueRay Target Price | 6.9 | -3.5% |